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INTRODUCTION 
Gout is ona a-F the�earliest disease entities to be described in 
medical writings •. Hippocrates noted familial distribution patterns 
and described ita cl:a"S.Sic symptomatology in the 5th century B.C. 
Empirical treatment employing colchicine was advocated by Alexander 
of Tralles in the.--&ttrc:entury A.D. A better understanding of the 
complex association batween clinical manifestations of gout and uric 
acid, carbohydrate:and: lipid metabolism has made rational treatment 
possible only very recently. 
Ample experimerrla: L and clinical data now available show a defi­
nite association be±ween disorders of purine metabolism resulting 
in hyperuricemia and frequent concomitant hyperlipidemia. A high 
incidence of both hypercholesterolemia and hypertriglyceridemia has 
been documented •. 
Elevated se.rum Lipids_ may explain, in part, clinical manifesta­
tions of atherosclerosis, occlusive peripheral and coronary arterial 
disease and vascular nephrosclerosis so common in approximately 
800,000 individuaLs_ suffering from gout in the United States. Renal 
failure, ischemic:. and degenerative cardiovascular disease are the 
most common cause� of: death in these patients. Therefore, the need 
for safe and reLiabl.e:- drugs that may be employed in the rational 
treatment of both gou±-,and associated cardiovascular alterations is 
abundantly clear. 
Allopurinol (hydroxypyrazolo(3,4-d)pyrimidine) (HPP) is by far 
the most promising drug now available for treatment of gout and 
1 
' 
related hyperuricemic disorders. It represents a new and rational 
approach to therapy by inhibiting an enzyme essential to uric acid 
biosynthesis. 
The correlation between gout and clinical manifestations of 
atherosclerosis associated with hypercholesterolemia and hypertri­
glyceridemia dictates that drugs used in treating hyperuricemic 
conditions should not elevate serum lipids. A further elevation 
of these parameters could increase the incidence of cardiovascular 
disease in highly susceptible gouty subjects. 
A possible causal relationship between therapeutic use of 
allopurinol and elevations· in�olood lipid values (human subject) 
was reported for the first time by this station in April, 1969 (1). 
A subsequent preliminary animal study indicated an apparent experimen­
tally provoked hypercholesterolemic hyperlipemia in rabbits adminis­
tered allopurinol (1). This study was initiated to examine the 






Gout or podagra was one of the earliest disease entities descri­
bed in medical literature. Although first use of the word "gout" 
occurred in the 13th century accurate descriptions of the disease 
were recorded by Hippocrates as early as the 5th century B.C. He 
noted specific familial, age and sexual distribution patterns and 
described the classic pathophysiology and symptomatology of acute 
gouty attacks in great detail. Empirical treatment of acute attacks 
of gout employing colchicine was advocated by Alexander of Tralles 
in the sixth century A.D. The diagnostically specific response of 
acute gouty attacks to colchicine has helped to distinguish it from 
otherwise similar clinical entities. 
Until very recently ignorance of the basic metabolic mechanisms 
pertinent to gout has limited our understanding of the disease and 
made rational treatment impossible. Progress was made primarily in 
improvement of diagnostic procedures and in answering questions 
concerned with heredity and pathophysiology of hyperuricemia in 
acute gouty attacks. Several reviews on the history, early diagno­
sis and treatment of gout are available (2); (3) ; (4). 
Serum Uric Acid Concentration 
Research efforts over the past thirty years have resulted in 
elucidation of a multiplicity of mechanisms which may result in 
hyperuricemia and its apparent clinical sequela. 
Jacobson (5) has s:ugg:_esied arbit rary normal limits for ur ic 
acid of 7 . O  mg/100 mL c
n 
se:rum for males and 6.0 mg/100 ml for fe­
males based on an extensiYapopulation survey. Seegmiller et il• (6) 
have shown an apprec:iatrLaoverlap of distributions in nongouty 
and gouty subjects between 6�0 - 7.5 mg/100 ml. Therefore, Stecher 
et fil• (7) have proposed tha1· emphasis be placed upon probability 
of development of gout as predicted by serum uric acid values, and 
not upon arbitrary di v.i sj orr of "normal II and "abnormal 11 1 evel s. 
Gout is a disease..ent-ity peculiar to man. Lack of hepatic uri­
case in man may play a r:ale. in augmenting gouty symptomatology but 
is not entirely responsibla for the disease syndrome since only a 
small fraction of the po:pulation is affected. In most mammalian 
species uricase oxidizes::.uric·acid, which is only sparingly soluble, 
to allantoin. This me±abo-Lic end product is quite soluble in body 
fluids and exhibits a higtr renal clearance. 
Hereditary Factors l!:l Hyperuricemia 
Impressive and. extensive evidence is available which points 
to a pattern of heredi.tary control of serum uric acid levels in 
families of gouty subjec±s. and. isolate ethnic groups. 
Genetic studies oF hyperuricemia in families of gouty patients 
led Smyth et fil..• (8) ta con-elude that hyperuricemia resulted from an 
autosomal dominant gene af low penetrance in females. This hypo­
thesis helped to exprairr why mean concentrations of urate in serum 
were found to be appreciably higher in male members of families hav-
ing gouty patients (9). However, Talbott (10) found the incidence 
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of hyperuricemia in genetically prone families variable and sugges­
ted that a polygenic trait was responsible. 
Absolute genetic control of familial tendencies has not been 
proven but impressive evidence published by O'Brien et g. (11) 
pointed to autosomal dominant polygenic factors being responsible for 
high positive correlations noted between serum uric acid levels and 
both weight and body surface area. Shyam et&• (12) reported 
significantly higher levels of uric acid in serum of patients with 
Down's syndrome in all age groups and in both sexes when compared 
to control subjects. No differences were noted in patients with 
Klinefelters syndrome or in parents of mongoloids. 
Becker and Wallin (13) have recently described a true congeni­
tal hyperuricosuria syndrome consisting of choreoathetosis, mental 
retardation, hyperuricemia and radiologic changes related to cerebral 
palsy. The condition is seen only in males and is inherited as a 
sex-linked recessive trait. 
Unusually high concentrations of urate in serum have been noted 
in the Chamorros of the Mariana Islands by Burch et al. (14), in 
Filipinos by Decker et al. (15), in the IVaori of New Zealand by 
D'Lennane et il• (16) and in the Blackfeet and Pima Indians of the 
United States by O'Brien et ll• (11). 
The discovery that mean serum uric acid levels of certain ethnic 
and reginal subgroups differ significantly f rom population means is 
further complicated by similar correlations with other nonhereditary 
factors. Rasch et al. (17) have shown an unexplained association 
5 
between indiv.i:dua-Ls with elevated serum uric acid levels and above­
average interiigence, achievement (military motivation) ,  and/or 
athletic ahi.li:ty •. 
It is abunoantly clear that stat�stical definition of an exact 
normal serum uric:: ac-id level or value to sharply demarcate normal 
from abnormal va1-ues would, at best, be an approximation. 
Wyngaarden (18) has suggested that theoretical sites of regu­
latory defec±s:: QT potential importance in the pathogenesis of hyper­
uricemia ara numerous and include both multiple genetic and nonhered­
itary factnr5 important in ultimate control of purine biosynthesis 
and uric acid:: excretion. 
Uric Acid Bio-synthesis and Metabolism J...o. Gout 
Garrod (i�J first documented the relationship between hyperuri­
cemia and gaut4, A multiplicity of regulatory defects may lead to 
hypernricemi.a and.. subsequent gout. However, defective purine meta­
bolism is conS-idered the primary biological mechanism in its patho­
genesis. lrres.pec±ive of etiology, deposition of uric acid in body 
tissues results:: ir r clinical manifestations of gout. 
Wyngaarden- (20) has reviewed, in depth, the de� pathway of 
purine synthes.i.s. and outlined less important pathways of purine 
nucleotide interconversion and of oxypurine and uric acid formation 
in explaining �o±ential pathophysiologic mechanisms of hyperuricemia 
in gout. Defa:iTs of individual reaction sequences may be found in 
reviews by Hartman tl al. (21) and Buchanan (22). Reichard et il• 
(23) have postulated comple� feedback mechanisms, called "Salvage 
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Pathways" wrrich may serve to regulate purine biosynthesis in certain 
gouty pati:entfu. Salvage pathways would contribute to excessive de 
.D..Q.YE.. puri.rre: synthesis, and resulting hyperuricemia, if adenine and 
quanine wera to react with 5-phospho-D- ribosyl-1-pyrophosphate to 
form the corresponding ribonucleotide directly. 
Hy�e.ruricemia results from multiple causal factors. Dietary 
intake or purines contributes to uric acid formation but rates of 
endogenous= de .Q.Q.Y.Q. biosynthesis and/or catabolism of cellular nucleo­
protein with resulting oxidation of purine ribosides to uric acid 
are considered primarily responsible for regulating plasma urate 
levels.. Me±ahol ic degradation and conversion of purine substances 
to uri·c· aci.ci i-s outlined in Figure ! • 
Disposition- of Uric Acid J..o. Gout 
Extrac.elTular fluids in most mammals supersaturate with uric 
acid at. concentrations above 6.4 mg/100 ml. Although supersaturated 
solutions may exist without crystal formation the normal level of 
diff·us.ibl.e- (miscible) uric acid in the extracellular fluid pool is 
about. one� gram whereas in tophaceous gout I evel s may exceed 35 grams. 
7 
Hyperuricemic individuals establish a dynamic equlibrium between 
plasma di�fus..ible (miscible) and tissue tophaceous (imniscible) urate 
pools •. Therefore, serum uric acid levels below 6. 0 mg% will generally 
result. in d.i:s.sol ut ion of tophaceous deposits and serum levels above 
this amoun+ in deposition of urate crystals. 
Urinary uric acid excretion in adult human males on purine-free 
diets ranges between 300 to 600 mg per day (endogenous biosynthesis). 
FIGURE I 
METABOLIC DEGRADATION AND CONV�RS\ON OF PURINE SUBSTANCES 
Nucl�i� Acips � Nµcleotjdes Nµcleqsides P'1rine Bas�s 
Adenosine Adenine Adenylic acid 
Jr t_· _____ _ _ 
� 
. � 
lnosinic acid----� lnosine 
Jl "--________ ___. 
Hypoxanth ine "' 
. � i 
Xanthylic acid----
t ___ I----,-----
;), Xanthos i ne -� 
Guanylic acid Guanosine 
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Data of �lTer et al. (24) indicate urinary uric acid excretion 
represents av.er- 75% of total body urate turnover. Extrarenal mechan­
isms acca_unt, fur the remainder. Gastrointestinal uricolysis result­
ing from ac±:ion· of bacterial flora. accounts for disposal of approxi­
mately 20G mg of uric acid daily yielding urea, ammonia and carbon 
dioxide as- primary end products. Effective bacterial degradation 
prevents appBarance of uric acid in stools unless antibiotic steri­
lizati.on ar the: gut or intestinal bacteriostasis has occurred. 
Measur.a hlE but insignificant extrarenal uricolysis in mamma­
lian tissue- due.. to verdoperoxidase has been reported by Cannellakis 
et al. (25) •. 
Theari:a.s.. concerning renal mechanisms responsible for uric acid 
excretion ha.s.:ed on the premise of complete glomerular filtration 
followed hY, highly effective (95%) tubular reabsorption of urate are 
no longer· hmahle. Gutman et fil• (26) have strong evidence to suggest 
complete reabsorption of filtered uric acid in proximal convoluted 
tubules.. Their evidence also suggests that excreted uric acid is 
produced entj.re1 -y by active distal secretion. 
Primary and Secondary Gout 
Symptom� of gout are common clinical sequela of hyperuricemia 
regardles.s af e.tiology. Gout is classified clinically as "primary" 
or  f1secandary" •. A classification of varieties of gout according to 
Wyngaarden (27) is outlined in Table I .  
The- pa.tho.genesis of hyperuricemia in primary gout is indepen­
dent of diverse disease states which may elevate plasma urate levels 
Primary gout 
Fami 1 ial 
TABLE· I 
A�CtAS:S.IFICATION OF VARIETIES OF GOUT 
Nonf ami lial� 
Secondary gout-
HematoLogic: d:i sorders 






Glomerulonephritis and pyelonephritis 
Saturni sm-
HypertenS:iYe: cardiovascular disease 
Glycogen s1orag� disease, Type I 
Juvenile g_ou±-,. choreoathetosis, and mental retardation 
Mi scel.laneous. 
Reproduced r·rom:: Advances in Metabolic Disorders. Vol. II, 
JX-· 56. 1965. 
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and has been attr i buted to both overproduction of purines and under­
excretion of uric acid or both. 
Talbott (28) has shown primary gout h i ghly familial in distri­
bution. A nonfamilial type of primary gout occurs occasionally in 
individuals from normouricemic families. Apparently rare cases of 
nonfamilial pr i mary gout result from disturbances in nonheriditary 
mechanisms involved in uric acid homeostasis. 
Secondary gout occurs when a disease or condition , excluding 
hereditary predisposit i on, is considered directly responsible for 
appearance of predisposing hyperuricemia. In these pat i ents sub­
sequent clinical symptoms of gout have been shown to. follow logical­
ly upon defects or conditions such as administration of hvoeruri­
cacidemic drugs (29) , obesity (30), starvation (31), chronic renal 
insufficiency (32), hyperparathyroidism (33), psoriasis (34) , gly­
cogen storage disease (35), sarcoidosis (36), polycythemia vera 
(37 ) ,  multiple myeloma (38) and leukemia or other hematopoietic 
system d i seases (39). 
Clinical incidence of secondary hyperuricemia has increased 
markedly since the introduction of antitumor agents which result in 
rapid resolution of large tissue masses with subsequent catabolism 
of cellular nucleoprotein to uric acid. Patients suffering from 
secondary gout differ from individuals with the primary form in 
several ways. Secondary hyperuricemia results in more severe vas­
cular nephrosclerosis and a higher incidence of renal calculi ap­
parently the result of increased uric acid excretion . Females show 
1 1  
a rri.gh-er- incidence of the secondary form than do males and topha­
ceuus: d:ep-cxsj ts are more widespread and numerous. 
Pu.hi:ished data have shown that pat i ents suffering from pri�ary 
gout. exh-i bit a markedly increased total body uric acid pool in the 
a:b-.s:enca- of- pathologic cellular breakdown. Therefore, Yu et fil.• (40 ) , 
arr the:- basi s of i sotope incorporation studies, have suggested that 
p-rimary g_out resul ts from substantially increased de !J.QYQ synthesis 
af purines· and uric acid. 
Uri.a Aci d and Lioid Metabol i sm 
It, i� wel l  recognized that hyperlipidemia and hyperuricemia 
ac u.r irr a� ·high percentage of patients suffering f rom both gout and 
showirrg- cfi n i cal man if es-tat ions of atherosclerosis and i schem i c 
heart d .i.�ease ( 4 1 ); ( 42). 
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Amdjsis of data from the Framingham popul ation- survey (43) 
ind.i.ca±erL that  gouty individuals had a frequency of coronary artery 
d.i:s:eas-.e: tv1.ice that of nongouty subjects. Avai lable evidence at that 
t. i me::: pcxir rt -ed to a causal relationship between c linical atherosclerosis 
in gout and hypercholesterol emia (44). 
Traut, (45) demonstrated urate deposits in both organized thrombi 
and i.n- prol : i ferated arterial intima . Kohn and Prozan (46) suggested 
that urai-es acted as a surfactant to pro��te subintimal lipid depos­
i.ti·orr resul1 i ng in occlusive arterial disease and atherosclerosis. 
Sub�equent- studies suggested a more precise association between 
hyperuric:emia and hypertrig lyceridemia (47) and later studies by 
Fasoli et al. (48) pointed to elevated serum 8-l ipoprotein l evels. 
ffecent findings of Barlow (49) do not lend support to current 
V4:ew� which hold triglycerides more important than cholesterol in 
al'.lY, association with uric acid levels. His data show hypertrigly­
c:er.i oemia is not found more frequently than hypercholesterolemia in 
gou.r. when adequate control groups of both normo- and hyperlipidemic 
sul±Jec±� are employed and effects of age and sex on serum lipid 
1avel�: are considered. I n  addition, he states that it does not ap­
p:ear- Justifiable to explain hyperlipidemia in gouty subjects merely 
as: an expression of atherosclerosis but suggests instead a metabolic 
and/or genetic association between observed changes in serum concen­
fr.a+i ons of lipid and urate in gouty individuals which i nvolves both 
clroi:e-si:erol 1 triglycerides and other contr i butory far.tor� �ur.h � !==;  
h1p.ertension, obesity and glucose intolerance. 
P-a: thoPenesis of Primary Gout 
rrOlJ± is cornnonly attributed to both overproduction of purines 
and underexcretion of uric acid. Sorensen (32) has coined the terms 
"pr. i mary metabolic gout" and "primary renal gout" to describe indi­
v,i .dual:s who appear to represent pure examples of either overproduc­
tj:orr or underexcretion of uric acid, respectively. However, Seeg­
mi:l[er et _itl.• (50) , in both group analyses and studies of individual 
case::- his.tories, have shown that the vast majority of gouty subjects 
exrrihit . evidence of both abnormalities. 
Garrod (1 9) , in 1876, first suggested that acute gouty attacks 
resu.l_ted. from an inflarrmatory response to sodium urate salts depos i­
ted in t i ssues. I t  is now generally accepted that gout is a crystal 
2 4 9 1 0 8 A...T{OT TA LIB RY 
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depos ition disease . However, it was not until the work of McCarty 
1 4  
et al . (5 1 )  was published in 1 961  that a logical explanation was avail­
able to explain acute inflammatory symptoms. They v iewed the acute 
gouty attack as involving a numbe r of crystal depos itions and host 
responses .  The inflammatory response was shown to be dependent on 
phagocytosis of mic rocrystalline sodium urate by leukocytes (neutro­
ph iles)  which ultimately lyse freeing certain kinin peptides. These 
peptides ul tiwately cause pain , vasodilatation, local necrosis and 
fibrotic proliferation which result in formation of subcutaneous 
tophi. 
The tophaceous nodul e is •«a pathognomonic lesion in classical 
gout. It  is composed of multicentric deposits of amorphous or  c ry­
stalline u rates arranged radially in a matrix composed of a polysac­
charide material , l ipid (cholesterol) , protein and occas ionally cal­
cium (52) e Howe l l et fil.• (53) have shown both non-palpable tissue 
deposits  and toph i to be monosodium urate monohyd rate. Bartels and 
�etossian (54 ) have reported a definite correlation between tophi 
formation and height of serum uric acid levels (above 8. 0 mg% ) ,  
degree and f requency of renal damage and duration of c linical symp­
tomatology. 
The solubility of monosodium urate appears reduced in sites 
predisposed toward tophaceous deposits. These include a rt icular 
and ear cartilages, synovial t i ssue , epiphyseal bone and heart valves. 
Tissue pH may play an important role in tophi formation since 
acidic media favors urate p recip i tation. Relatively avascular areas 
such a:s=-: the: ears or toes tend to be "ac i d i c" because of the i r  reduced 
tem�e:rature&, , l ow oxygen tens i on and dependence on g l ycol ysis , w i th 
result i ng La:e-tic ac i d  formation , for energy product i on. 
Renal� pathol ogy i s  common i n . pat i ent s suffering from gout and 
i. s  the: evem.ua-1 cause of death in 25% of these ind i v i dual s. Soko­
l off ( 5.Z) has. publ ished data wh i ch extend and s trenghthen the tra­
d i t . i anal� v. i .e ..w that renal l es i ons resul t from precip i tat i on of urates 
wi:th  obs±ruc± i on of col l ect i ng tubu l es, and secondary necros i s , 
f i brasi� arrd atrophy of proximal convol uted tubul es. A typical and 
di.at.inc±-i v.a gl omerul oscl erosis may be a react i on of the kidney t o  
i ncrea--sed:. ri l trat i on o f  uric ac i d. Renal damage in gout i s  sa i d  to 
h i nge- more_. upon uric acid sol ubi l ity i n  tubu l ar fl u i d and urine than 
i. ts srrLuni 1:i.ty i n  p l asma. 
D i aono-s- i ff and Treatment of Gout 
Ili:agnos .i s  of gout i s  accompl i shed by careful ana l ysis and eva l u­
at i on· o::F ( l) cl i nical symptomatol ogy ( 2 )  addit i ona l earl y supporting 
ev i dence- (3:-) apoearance of l ater deve l oo i ng d i agnost i c  criter i a  and 
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(4)  po:.s:.it- i v.e. l aboratory and/or rad i ographic f i ndings. 
Gou±:. shou l d  a lways be cons i dered i n  cases of acute ,  unexpl a i ned 
art i cular distress i n · postmenopausal women or prev i ousl y  heal thy 
men ., CTas:si c-. c l in i cal find i ngs of the - acute  attack a re usual l y  
suff i -c=i ·en+_ hr establish a d i agnos i s  i n  gout . A h i sto_ry of fam i l i al  
hyperuri :cemi a is particul ar l y  useful  in mak i ng an earl y d i fferen tial 
d i a-gno_s.: i s be.tween acute art i cular gout, chondrocal cinosis (pseudo­
gout) and rheumatoid arthritis. Al though changes i n  serum ur i c  
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acid levels are not considered causal in precipitation of acute 
attacks hyperuricemia is present in all but 5% of gouty subjects 
and is considered a valuable . diagnostic aid. The presence of urate 
crystal s  in synovial fluid aspirat�d from an inflamed joint during 
an acute attack or from tophi are absolute and reliable diagnostic 
criteria for gout. 
Colchicine is so dramatic and selective in its ability to alevi­
ate joint pain in acute gouty attacks it is used as .a diagnostic 
tool. However , the test is not infallible since occasional gouty 
subjects fail to respond and false positives occur in about 5% of 
patients suffering from nongouty arthritic disorder? •  
Radiographic changes characteristic o f  cystic joint , cartilage 
and epiphyseal bone destruction, caused by replacement of calcium 
salts by monosodium urate, are common in chronic gout. 
The most com�on cl inical symptoms and laboratory findings noted 
in primary gout are l isted in Table  !' I. 
Colchicine 
Colchicine is an alkaloid of Colch i cum autumnale (meadow 
saffron). A lthough the drug was not isolated by Pelletier and 
Caventou from colchicum until 1 820 , crude plant preparations were 
prescribed for pain of articular origin as early as the s i xth century 
by Alexander of Tralles. Colchicine will dramatically and specifi­
cally terminate an acute gouty attack. It does not have analgesic 
or  uricosuric properties and is not capable of altering either serum 
uric acid levels or amounts of diffus i ble (miscible) uric acid in 
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TABLE 1 1  
CL I N I C AL SYMPTOMS AND LABORATORY F I ND I NGS NOTED I N  PR I MARY GOUT 
ART I CUL AR SYMPTOMS 
Acute articu l ar pain 
Onset sudden, severe and often nocturnal 
Usually monoarticul ar invol vement 
Metatarsophalangeal joint of great toe 
Ankle 
Knee 
Wr i st 
Invo lved joints {ender, swollen, hyperemic 
Pronounced limitation of motion (ankylosis) 
Cystic changes in epiphyses of bone 
Jo i nt and cart i lage destruction 
Presence of urate crystals in synovial fluid 
Acute episodes fo llowed by periods of complete remission 
rv-rn A 1t nT 1 1'\ I II l\ n  l'\ ('\ � ftnl l l'\ ll 'T' t f'\11 1 1"  / n r l\ l A I  l l>. 1 1 1 1"\1 \ l ,I A , II I T \  
&..I\ 1 1 1 n ru 1 1  I V VL.. lll l v v , � ,, L.. I v n  I I Vl ll v  \ I  I L l ll nL I · � II UL V LIVIL I II  I / 
Al bum i nu ria 
Uric acid urolithiasis 
Arterio lar nephrosclerosis 
Glomeru lonephritis 
Pyelonephrit i s  
Delayed phenolsulfonphthalein excretion 
SYSTEM I C  REACT I ONS  
Moderate fever 




Ano rex i a  
Leukocytosis 
Hyperur i cemia 
Presence of subcutaneous tophi 
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tha tohl. l body poo l . The exact mechan i sm by wh i ch i t  exe r t s  i t s 
anti.-i nf l arnrnato ry act i on i s  st i l l  un known and rema i n s as one o f  
the: cr l des t myster i es i n  med i c i ne .  
Seve ral theo r i es have been p roposed i n  a n  at t empt t o  expl a i n  
tha ant i - i nf l ammato ry act i on of co l ch i c i ne .  Seegm i l l er e t  al . (55)  
amt Howel l e t  fil.• ( 56 )  have suggested that · the  d r ug i nh i b i t s l eu ko­
cy,te:- metabol i sm and subsequent el evat i on s  of  1 act i c ac i d  wh i ch wou l d 
atherw i se occu r as a resu l t of  u rate crystal  phagocytos i s  dur i ng an 
acute gou·ty at tac k .  Ma l aw i  s ta (57 ) has sugges t ed that co l ch i c i ne  
sup.p.r esses p i nocyto s i s  i n  n�ut roph i l es mak i ng phagocytos i s  of  u rate 
c:riystal s i mpo ss i b l e . Such a mechan i sm wo u l d  e ffect i ve l y bl ock the 
abiI H y  of affected l eu kocytes to pa r t i c i pat e  i n  t he i nf l ammato ry 
m:rnpo n se . 
Although the  exact b i ochem i cal step o r  steps  i nf l uenced by 
ca tch i c i ne a re un known they are  i nd ependent  o f  ant i m i to t i c  act i v i ty .  
The total amount  of co l ch i c i ne- usual l y  r eq u i red to term i nate 
an ; acu te go uty at tack ranges between 4 . 0 to 8 . 0  mg . An i n i t i a l 
dose- o f  0 . 5  to 1 . 0 mg i s  fo l l owed by 0 . 5  mg doses each hour unt i l  
r.e.su:Lu t i on o f  t he attack occurs  o r  tox i c  symptoms en sue . 
Uri -'co su r i  C Aeen ts  
Ur i co su r i c  d rugs are , i n  essence , u rate d i u re t i cs .  Desc r i bed 
aff a- group they are  o rgan i c  ac i ds wh i ch compet e  w i th sod i um u rate  
f'or- an -i on i c  t ran spo r t  s i t es i n  t he neph ron .  The  t h erapeu t i c  
object i ve o f  u r i cosu r i c  d rug adm i n i st rat i on i n  gou t  i s  reduct i on of 
d i ffus i bl e  ( m i sc i bl e ) u r i c  ac i d  i n  the  ext race l l u l a r  f l u i d  poo l . 
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Cl inically, Gutman and Yu (58) have shown dram�tic success in resolu­
tion of subcutaneous tophi in gouty subj ects when serum urate levels 
were l ower ed to 6. 0  mg% by administration of uricosuric drugs c The 
two most commonly employed drugs in this class are probenecid 
(Benemid ) and sulfinpyrazone (Anturane). 
Probenec i d  was one of a number of drugs developed by Beyer and 
his associat es ( 59)  i n  an extensive and systematic study to find a 
compound that would effectively inhibit the rapid renal excretion of 
penicil lin. Although probenecid will effectively inhibit rapid ex­
cretion of penic i llin it is now used cl i nically almost exclusive l y  
for its uricosur i c  pro perties . 
Probenecid� U. S. P .  ( Benem i d ) i s  av� i l A h l P �nmmPr� i � ! ! y  ; �  0 . 5  
gm scored tablets. i n  the treatment of chronic tophaceous gout 
0. 25 gm of the drug is administered twice daily for one week, 
initially, and 0 . 5 gm twice daily  thereafter. 
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Burns et il• (60) described the uricosuric activity of sulfin­
pyrazone, a sulfoxide metabolite of phenylbutazone, in 1 958 . Although 
sulfinpyrazone ( Anturane )  lacks the analgesic and anti-inflammatory 
properties of phenylbutazone it reta i ns the potent uricosuric activity 
of its congener. Gutman (61 )  has published a deta i led descr i ption of  
sulfinpyrazone therapy for chronic gout. 
Opinions regarding indications for uricosuric therapy vary 
considerably. The only unequivoca l indication for the i r  use appears 
to be in tophaceous gout . - Wost author i ties do  not consider asympto­
matic hyperuricemia an indication for therapy since evidence to 
show that uricosur ics  either ameliorate or prevent renal damage in 
goul is l acking. 
I nhibitors of  Ur i c  Acid Synthes i s 
I deally, rational treatment of  gout would  invo l ve pharmaco l ogi­
cal correction or amelioration of basic ce l l u lar metabolic defects 
which result in hyperuricemia and its ultimate c linical seque la. 
·At the present lime rational treatment is aimed at inhibition of  
accel erated purine synthesis and uric acid formation known to  occur 
in gouty subjects. 
Orotic Ac i d  
Fal lon et al. (62) have shown that l arge doses o f  o rotic acid 
gcruly subjects . The mechanism of  action of  erotic acid is unknown . 
However, Delbarre and Auscher (63) have evidence to suggest that it 
i.nhibits de !lQ.'LQ. purine bio synthesisc 
C linical use of the compound is ext reme l y  l imited because of  a 
high incidence of  adverse side effects. Hugul ey et al . (64) have 
reported multip le  cases of renal uro l ithiasis and Creasey et fil• 
( 65 )  have evidence to suggest a causal relationship between erotic 
acid admin i stration and fatty infiltration of the l iver in labor­
atory animals. 
L-Glutamine Anal oes 
Two structural analogs of L-gl utamine, 6-diazo-5-oxynorl eucine 
(DON) and azaserine, have been shown to e ffective ly  inhibit glycine-
1-1 -4c incorporation into uric acid in man and resul t in reduction of  
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both serum and urinary urate levels (66); (67) . Although these 
compounds are useful research tools they cannot be employed clini­
cally because both are highly toxic to buccal and gastrointestinal 
mucosa. 
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Allopurinol (4-Hydroxypyrazolo (3 , 4-d)pyr i midine) 
Allopurinol (Zylopr i m) has found extensive c l inical us e in 
t r eatm ent of hyperuricemia and hyperuricosuria of diverse etiology. 
KLinenb erg e-t a l .  (68) have described th e drug as a new and truly 
rational approach to therapy in gout and r elated hyp eruricemic 
conditions. 
Allopurinol is a close structural ana l ogue of hy poxanthine and 
a potent i nhibitor of xanthine oxidase which has b e en demonstrated 
nec essary for conv ersion of hypoxanthine and xanthine to uric acid 
in vivo. 1\ntihyp eruricemic. activity follows blockade of this 
essential st ep and results in reduction of both serum and urinary 
uric acid levels by inhibition of �� novo synthesis � not bv increased 
urinary l oss, as with uricosuric ag ents. 
Available evidenc e indicates allopur i nol does not d i srupt bio­
synthesis of vital pur i n es and i nhibits only those bioch emical steps 
in purine catabolism which inmed i ately prec ed e uric acid formation . 
Chemist ry 
Xanthine oxidase is respons i bl e  for catabolism ( i nact i vation) 
of' 6-mercaptopur i ne (6-MP) and related th i opur i n es used in canc er 
chemoth erapy. A structural analogue of the purine base hypoxanthin e, 
4-hydroxyprazol o (3, 4-d) pyrimidin e, was or i ginall y  on e of a numb er of 
pur i ne analogues, that act as xanth i ne ox i dase inh i bitors i.o. v i tro , 
s�re ened by Hitch i ngs and Elion (69) for potential us e as an adjuvant 
in anti-neoplast i c  disease the rapy . The i r  aim was to increase thera­
p eutic efficacy of purin e analogs such as 6-MP by sl owing rates of 
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me{abolic inactivation by i nh i bition of xanthine oxidase . Elion 
(70) chose 4-hydroxypy razolo(3, 4-d)py rimidine  fo r lo. vivo studies 
after analysis of preliminary data indicated that it was relatively 
rron-koxic. The compound was initially refe r red to as 1 1B . W . 56-158 1 1  
(Welicome Research Labo rato ry ) ,  late r as "HPP" , and has now been 
giMen the gene ric name allopurinol . Falco et al. (7 1 )  synthesized 
the.. py rozolo (3, 4-d)py rimidine se ries f rom which the compound was 
obtained in 1956. 
Allopurinol is a structural analogue of the natural purine base, 
hypuxanthine, diffe ring by transposition o f  carbon and nit rogen 
atoms in the seven and eight positions (Fig. I I ). I t  is both a 
pu+ent inhibitor of, and a substrate fo r ,  xan thine ox i dase (72). 
The compound acts as a competitive inhibitor o f  the enzyme at l ow 
inhibito r levels (73) and a noncompet i tive inh i bito r at higher con­
c:errlrations (74). The p roduct of its xanthine oxidase-catalyzed 
ox i :dation is a xanthine analogue, oxypurinol o r  alloxanth i ne, 4, 6-
dihydroxypyrazo l o (3, 4-d)pyr i midine, which is  also an i nhibitor of 
xanthine ox i dase (75);  (76). 
Available evidence ind i cates that neithe r allopurinol no r oxy­
purinol exhibits binding to plasma proteins and that tissue and 
organ concentrations do not diffe r from equal distribution in total 
body water ,  with ·the exception o f  b rain wh i ch exhibited about half 
the- amounts isolated from o the r  tissues (75). 
Taggart  (77) has shown that oxypurinol i s  not a member of the 
"organic acid system" and Weiner et al. (78) have pub lished data 
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F I GURE 1 1  
CHEM I CAL STRLCTURES AND REL AT I ONSH I PS BETWEEN ALLOPUR I NOL , 
OXYPUR I NOL AND TERM I NAL COMPOUNDS I N  THE B I OSYNTHES I S  OF 
UR I C  AC I D  
HYPOXANTH I NE XANTH INE 
f = l nh ib i  t i on 
IB IC AC ID 
l Mos� mammals: 
IB ICASE exc lud ing 
man 
Reproduced from: Thibodeau et al. , S. Dak. J. Med. 22: 22, 1969. 
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which seperates it, chem i cally, f rom uricosuric drugs . El i on et fil• 
(75) have suggested that oxypurinol appears mo re as an analogue of 
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uric acid than xanthine when considering functional groups in the 
pyr i midine ring or  the presence of an unshared electron pair in the 
reg i on of the purine-8 position. Their data suggest that this unshared 
e-Lectron pair may be the structural feature wh i ch determines oxypur­
ino-1 behavior .  
Pharmacolo�y 
Pharmacologic effects of allopurinol adm i nistrat i on are, almost 
w i thout exception, directly _ related to .its blockade of terminal bio­
chemical reactions in de � uric acid biosynthesis via xanthine 
o:xidase inhibit i on. 
Allopurinol and i ts i.D. v i vo ox i dative metabolite, oxypurinol 
(a:D oxanthine) , are both potent inh i bitors of xanthine oxidase (75). 
Therefore, pharmacologic half-life of effective xanthine oxidase 
ihhibition i s  dependent upon both renal clearance of administered 
a1Topurinol and rate of oxidation to, and subsequent excret i on of, 
oxypurinol. Oxypurinol has been shown to be a less effective in­
n i bitor than allopurinol (79) but i s  of cons i derable pharmacolog i c  
i mportance because of its longer half-l i fe .  Accumulation occurs as 
a:: consequence of low renal clearance. Fur the r , direct inactivation 
o:F xanthine oxidase by both allopurinol and oxypurinol influence 
uTt'imate clinical responses. Rundles et al. (80) have shown that 
endogenous synthesis of xanthine oxidase is neither induced by treat­
ment with allopurinol nor inhibited because of the subnormal activity 
ma i nta i ned after its administration. 
Efficacy of allopurinol as an i.D. vivo xanthine ox i dase i nhi­
bitor was first confirmed 1 n  results published by Rundl es et il• 
(81) in 1963. They noted a marked reduction in dosage requirements 
of sulfur-contain i ng hypoxanthine anal ogues (6-MP)  needed for adequ­
ate therapeutic response in cancer chemotherapy i f  the compounds 
were administered concurrently with allopur i no l . Enhancement of 
6-MP activity was correctly attributed by E l i on et al . (82 )  to .i!l 
vivo suppression of xanthine oxidase activity preventing oxidation 
of 6-�/P to its i nactive 6-thiour i c  metabolite. I n  addition they 
noted striking reduct i ons i n  serum and urinary uric acid levels  
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not observed w i th admin i stration of 6-MP alone . White (83 ) has shown 
a llopurinol compl ete ly  ineffectual when administered a lone as an 
antineoplastic drug. Subsequent data published by Shaw et  il• (84 ) 
extended and corroborated these findings. 
A consistent dose-dependent reduction in both serum and urinary 
uric acid l eve l s  has been shown to occur fol l owing initiation of 
allopur i nol  administration in gouty subjects (85). 
Dosage levels of al lopurinol needed to reduce hyperuricemic 
blood l evels to normal ranges vary from 400 to 600 mg per day in severe 
tophaceous gout to 200 to 300 mg per day, in divided doses, for 
subj ects w i th mild forms of the disease . Serum urate l evels fall 
quite sl owly after init iation of therapy and increase to hyperuri­
cemic levels only gradual ly after drug withdrawl because of prolonged 
oxypurinol hal f-l ife (sl ow renal clearance) .  
Recent data publ i shed by E l i on et fil• (75) suggested augmented 
rrenat clearance of oxypur i nol dur i ng ur i cosur i c  drug therapy. They 
no±ed a def i nite decrease i n  xanthine oxidase inh i bit i on by oxypur­
inol: dur i ng comb i ned therapy but often found such treatment effec­
t�i ve i n  ach i ev i ng minimal serum urate l evels  in gouty patients with 
nephropathy. Klinenberg et ill.• (86) found a l lopur i nol used i n  con­
junct i on w i th uricosud c  drugs al l owed max i mal  total purine excre­
t-..i .on •. Yu and Gutman ( 85) reported al l opurino l capabl e  of reduc i ng 
plasma ura.te l evel s i n  the presence of gouty nephropathy sufficient 
to render u ricosur i c  drugs i neffective. 
Resu l ts of renal stud i es i ncl uding g lomeru lar fil tration rate 
sign i f i cant differences when compared to resu l ts obtained prior to 
ini :t .iation of therapy . 
Data publ i shed by Kl i nenberg et al. (86) a l so suggest that 
a11Dpurinol admin i stration which resul ts in excret i on of three 
(rather than one) purine metabol ic end products, each w i th its inde­
pEildent sol ubil ity l evel , provides a more favorable cond i tion for 
e:llimination of rel atively insol ub le  uric ac i d. Danger of urinary 
calcuri  format i on dimin i shes further as urate excretion is  reduced 
duri ng therapy . Amounts of al lopurinol and oxypurinol excreted are 
well within l imi'ls of their respect i ve sol ubi l ities i f  administered 
at� recommended dosage level s. 
Tox 1  col oey 
Al though spec i fic studies of possibl e diverse function have 
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not been published, xanthine ox 1 dase is known to be a versatile 
enzyme capable of acting on a variety of substrates (87). There­
fore , i..o. vivo inhibition foll owing allopurinol administration could 
theoretically precipitate multiple clinical complications. In all 
probability, however, therapeutic dosage levels of allopurinol do 
not completely inhibit .i.n vivo xanthine oxidase activity . Further, 
xanthinuric subjects who show a complete lack of xanthine oxidase 
activity from birth live in comparatively good health. 
There is now a wealth of experimental data, from both animal 
and clinical research endeavors to substantiate initial reports 
d escribing allopurinol, in general, as an exceptionally well tolera­
ted drug (88); (89) ; (90). 
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Results of early clinical studies by Yu et .ill.• (85), and others, 
risted an increase 1 n  number of acute gouty attacks during initial 
stages of allopurinol therapy �s the most troublesome complication · 
encountered . Although attacks usually became shorter and decreased 
in severity as therapy continued, p rophylactic administration of 
colchicine is now recommended when allopur i nol therapy is initiated . 
In general, drug idiosyncrasy has not constituted a serious 
deterrent to allopurinol administration. rvlost drug reactions attri­
buted to allopurinol, including fever, chills, pruritus, nausea and 
vomiting have been minor and transient. 
Severe reactions, although rare , have been reported and include 
impaired renal function (88), and leukopenia (86). Adverse effects 
on _hepatic iron storage (91); (92) and impaired iodine metabolism 
( 93) have been reported fol lowing a l lopurinol administration • .Pin­
nas (94) has reported a possib le  association between macul ar l esions 
and allopurinol and Thibodeau et il• (1) have suggested a possib le  
causal rel at ionship between its use and subsequen t hyperlipemia. 
The LD50 for al lopurinol in mice is reported to be 160 mg/kg 
i.p. and 700 mg/kg p.o. The acute LD50 in rats is l isted as 750 
mg/kg i.p. and 6000 mg/kg p.o. (95). 
Teratogenic and reproductive studies with both rabbits and rats 
showed a l lopurinol administration had no effect on l itter size, num­
ber of stil l births or ma lformations. Mean weights of young at birth 
and at three weeks postpartum were not affected (95). 
Indicat ion s  for Use 
Absol ute and definite clinical indications for therapeutic 
and/or prophyl actic use of al lopurinol either alone or in combination 
with uricosuric agents , colchicine, phenylbutazone (Butazolidin), 
corticosteroids or synthetic nonsteroidal  an ti- i nf l ammatory agents 
such as indomethacin are not yet clearly formu l ated. 
Allopurinol is not an i nnocuous drug. A l though stud i es to date 
have shown it to be remarkably well tolerated by most subjects long 
term effects of administration are not known . Therefore , strict 
at ten tion should be given to recommended indications for its use and 
until more definitive investigations are comp l eted ind i scriminate 
c-l inical use in other hyperuricemic states is contraindicated. 
Tab le  I I I l ists pre$ent l y  recommended indications for a l lopur­
inol administration . I t  should  be noted that pediatric use is 
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TABLE 1 1 1  
RECOMWENDED INDICATIONS FOR ALLOPURINOL ADMINISTRATION 
Familial or nonfamilial primary hyperuricemia (gout) 
Secondary hyperuricemia (gout) due to: 
Myeloprol iferative d isease 
Polycythemia vera 
Leukemias 
Radiat i on therapy or antineoplastic drug use 
Pd mary uric acid nephropathy 
Prophyl axis of urate nephrooathy 1 n  neoolastic disease states 
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Uric acid urolith i as is and ·tissue urate deposition in gouty arthrit is 
Concom i tant use with antineoplast i c drugs to reduce requ i red dosages 
Concomitant use with ur i cosurics to obtain maximal purine excretion 
Control of uric acid urolithiasis in patients with hyperuricosuria 
Prevention of acute renal failure secondary to urolith i asis 
contraindicated except in cases of secondary hyperuricemia in 
children with confirmed ma lignancy. Avail able teratogenic and 
reproductive studies employing laboratory animal s have shown 
all opurinol f ree of adverse effects. However , the effects of 
xanthine oxidase inhib i tion on the human fetus are  unknown. 
Therefore , all opur inol shoul d  be used in pregnant women or women 
of childbearing age onl y if potent i al patient benefits are weighed 
against poss i ble fetal risk .  Individuals who show severe reactions 
such as  hepato toxic i ty ,  impa i red renal function or leukopenia 
following in i tial allopurino l adm i n istration shou l d  not be restarted 
on the drug . 
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EXPER I MENTAL METHOD 
Expe rimental Animals 
£ixteen purebred, Dutch Black and Grey, virgin doe rabbits 
weighing 1435 to 21 1 4 grams were utilized in this  investigation. 
A ll  animals received an extensive initial clinical examination and 
were found ale rt , active and apparently di sease-free. 
Experimental animals were individuall y  housed in stainl ess 
steel batteries and maintained on a commerc i ally available pe l leti­
zed rabbit diet 1 and mineral supplement2 • Feed and wate r were pro­
v i ded ad l i b i t um. Animal quarters were air conditioned to m i nimize 
environmental temperature fluctuations. 
Treatment and Control Grouos ·-- ---- ·-- -- ----
Fon owing a two-week adaptation period a table of random numbers 
was employed to assign animals to either experimental or control 
groups each containing six does. Experimental animals received 50 
mg of commercially availabl e allopu rinol suspended in one ml of dis­
tilled_ water ,  orally, daily for 14 days. Control group does received 
an equal. amount of Normal Sal ine for a similar period employing iden­
lical techniques. 
D rug Preparation : Oral Administrat i on 
A lJ"opurinol employed in this study was obtained commercia lly in 
tablet form. Tablets were crushed in a mo rtar and pestle and the 
1Rabbit Fami l y  Ration. Albers Mil ling Company. Los Angeles, Calif. 
2
carey Mine ral Suppl ement Spools with Sal t .  Carey Salt Co. 
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finely ground powder suspended evenly i n  water i mmediately prior 
to administration. Highly alkaline d i luent , wh i ch might have result­
ed i n  gastric irritat i on ,  would have been necessary for compounding 
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a true drug sol ut i on. Probl ems commonly associated w i th repeated 
passage of gavage tubes were eliminated by use of a tuberculin syringe 
for oral drug adm i nistration employing a technique previously describ­
ed (96) . 
Collect i on of Data 
An i mal s were we i ghed when assigned to exper i mental or control 
groups, then i solated from other experimental animals for seven days 
prior to in i tiation of the 1 4 -day treatment period. Animals were 
weighed a total of five t imes : 
1. Seven days prior to i n i tiat i on of treatment (Day 1) 
2.  The first day of drug admin i stration (Day 7) 
3. The seventh day of drug administrat i on (Day 1 4 ) 
4. The 1 4th  day of drug administration (Day 21) 
5. Seven days post-treatment (Day 28) � 
B lood was d rawn for analysis of lipid, ur i c  acid and hemogram values 
on days 7, 1 4 , 21 , and 28 . Lip i d  values monitored were total choles­
terol and trig l ycer i des; hemogram values incl uded packed cell volume 
and total hemoglob i n. 
Unanesthetized rabbits were suppinated and immobilized on a slatt­
ed small animal holding board. The thorax was shaved and painted 
with an aqueous solution of 1: 750 Zepharin Chloride before 10 ml 
of blood was drawn by cardiac puncture employing aseptic techniques �  
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A 20 gauge needle was used to minimize hemo lysis and sodium heparin was 
employed as an anticoagulant. 
Packed cell volume and hemoglobin values we re determined immedi­
ately. Whole blood was cent rifuged, plasma decanted and then quick 
frozen for analysis of lip i d  and u ric acid level s  at a later date. 
Hemoglob i n  and Packed Cell Vol ume Determinat i ons 
Measu rement of total hemoglobin is a routine and commonly employ­
ed technique in clinical laboratory medicine . The Cyanmethemoglob in  
Method is recommended as superior b y  the Cl inical Pathology Standards 
Program of the Col l ege o·f American Patholog i sts and was employed i n  
this study (97). 
Cyanmethemoglobin col or compl exes are remarkably stabl e and 
possess excellent spectral characteristics . A l inear five-oo i n t 
standard cu rve, blank, 5, 1 0 ,  15 and 20 g rams percent hemog l obin, 
was p repared employing a commercially ava i labl e cyanrne -themoglobin3 • 
Absorbance in opt i cal density figures or percent t ransmission of the 
standard was found to be equivalent to 20 gm% hemogl obin when 0. 02 
ml of b lood was added to 5 .0  ml of a reagent supplied by the same 
company. A Beckman Model DB-G spect rophotometer  set at 540 mµ was 
employed. 
Determinat i on of total hemog l obin in unknown samp l es was ac­
complished by add ing exactly 0 . 02 ml of blood to 5.0 ml of reagent, 
3 
Hycel Cyanmethemoglobin Dete rm i nat i ons. Hycel , I nc. Houston, Texas 
inverting several ·times , and reading duplicates against a Reagent 
B lank  at 540 m�. Readings were transferred to a standard curve and 
total hemoglobin concentration in gm% obtained directly. Total 
hemoglobin measured by this method included oxyhemoglobin , carboxy­
hemoglobin and methemoglobin and was found accurate in practice to 
3% variation. The only case in which cyanmethemoglobin would not 
represent total hemoglobin is in sul fhemoglobinemia ( 97). 
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The cyanmethemoglobin reagent empl oyed effected a rapid hemo l y­
sis of erythrocytes and formation of a stable co l or complex. Micro­
scop i c  examination of the reagent-blood mixture verified complete 
hemolysis indicating an absence of certain abnormal cells known to be 
resistant ·to lysinQ in this media. Cells resistant to hemo lvs i s are 
associated with hemolytic and sickle ce l l  anemias and traits , thal­
assem i a  major and mino r ,  hepatocellular jaundice, hemoglobin C disease 
and cases of reversed al bumin-globulin ratio s. 
Packed cell volume values were obtained employing standard micro­
techniques .  Experimental blood samples were well mixed and introduced 
into heparinized microhematocrit capil l ary tubes. Tubes centrifuged 
at 3000 rpm for five minutes showed distinct separation of erythro­
cytes from plasma . Values were obtained directly from scales impr i nt­
ed on the spec i alized centrifuge base4 • 
Determinat i on of Total Cho l esterol (Direct Method) 
Cho lesterol is soluble in many organic medias including ether ,  
4Autocrit Centrifuge . Clay Adams Company. 
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chloroform, acetic anhydride and acetic acid . Differing but charac­
te r i stic solubility patterns in t hese various media have led to 
many techniques for isolation and separation of cholestero l f rom 
who l e  blood and numerous blood f ractio ns. The t echnique emp l oyed 
i n  t his study is a modif i cation of the method of Schoenheime r  and 
Spe r ry (98) .  
A commercially available5, stable, Lieberman-Burchard reagen t 
was used for de termination of tota l cholesterol in plasma. The 
reagent consists of 14 . 5% sulfuric acid in 41. 0% acetic acid and 
43. 0% ace t i c  anhydr i de .  Reagen t stabil i ty i s  apparent l y  achieved 
by a process of compounding unde r controlled t emperature cond i tions. 
Use of this reagen t will result i n  a reaction specific fo r  the double 
bond between C5 and C6 on ring B of the stero l  molecule p roduc i ng a 
typical green-blue color . 
Timed sequence of react ion rates was no t c�nsidered i mpo r tan t 
since readings made within 10 minutes following color developmen t 
were always stable. All sampl es were r ead within this time period . 
Absorbance character ist i cs of the reaction a t  625 m� followed Beer-
Lambe rt ' s  Law between O - 300 mg%. 
A .  Methodo l o�� 
5 
1. Accurately pipette 0. 1 ml of plasma into marked cuvett e . 
Place 0.1 ml cholesterol standard (200 mg%) into marked 
cuvel te. 
Hycel Choleste rol Reagen t. Hycel, Inc. Houston, Texas 
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Z.. To each test tube or cuvette add 6 . 0  ml cholesterol reagent. 
Mix well by shaking. 
3 • . Place cuveHes in water bath at 37 °c . for 20 minutes .  
4.. Read optical density against reagent at 625 m}J • 
B .  Ca lculations 
l. "A' ' - Optical density of unknown 
2· . 1 1B 1 1  - mg% value of control or standard 
1-. "C" - Optical density of standard or cont rol 
then; A X  B = mg,,�, Unknown 
C 
Tab1.e I V  indicates reproduc i  bi 1 i ty of the Liebermann-Burchard color 
reac.t i on employ ing Hycel stab l e cholesterol reagent. 
Lend s_ itself to a relatively simple methodology. However , the ques-
. tion of col or development produced by blood constituents other than 
cholesterol is possible if bilirubin levels are highly elevated or 
cnns·i .derable hemolysis is evident. Elevated bilirubin levels did 
rrot occur i n  either experimental or control animals used in this 
s:.tudy and precautions were taken to minimize hemolysis when blood 
was collected. Adherence to accepted laboratory technique decreased 
the possibility of inadvertent transfer of red cells with the plasma 
sampl.e or addition of moisture to the reaction. Such errors could 
faLsel y elevate apparent cholesterol values. If it had been necessary 
tu use_ plasma showing significant hemolys i s, values wou l d  have been 
rechecked using an alcoholic extract. 
Specif i c  for the doub le  bond between c5 and c6 on ring B of the 
Concent rat i on of 
Standard 
1 00 mg% Standard 
200 mg% Standard 
300 mg% Standard 
TABLE I V  
REPRODUC I B I L I TY  OF THE L I  EBERMA�·� :-BURCHARD COLOR REACT I ON 
EMPLOY I NG HYCEL ST ABLE CHC·LESTEROL REAGENT 
Average Std . Dev . 
1 00 . 1 mg% 
1 99 . 8  mg% 
300 . 4  mg% 
Recovery of AddE�d Known 
Added 
40 - 300 mg% 
1 . 3 m� 
2 . 3  mg% 
3. 5 mg% 
Recoveri 
94 - 99 % 
Range 
97 - 1 03 mg% 
1 95 - 205 mg% 
290 - 31 0 mg% 
w 
0::) 
sterol molecule the reaction 1 s  not affected by uric ac i d , amino 
ac i ds, v itamins ,  c reatinine , creatine , protein , carbohyd rates , or 
electrolytes. No agents presently known , i ncl uding allopurinol , 
w i l l  depress the reaction. 
Determinat i on of P l asma Uric Acid Leve l s  
Determ i nation of uric ac i d  levels in various body fluids is a 
rout i ne procedure for most cl i nical and paramedica l research labora­
tories. It  i s  unfortunate that a major i ty of clinical (hospital )  
laboratories employ colo:imet r i c  procedures , of questionable accuracy � 
dependen t  ent i rely on format i on of a blue-colo red complex resulting 
from reduction of phosphotung;tic acid by ur i c  ac i d. Blanch and 
procedures a lone are almost always i ncorrectl y e levaled due to the 
p resence of other blood constituents which yield similar color com­
pl exes. 
The method of determ i ning true uric acid l evels employed in 
this investigat ion is a modification of an enzymatic procedure f i rst 
described by Praetorius and Poulsen (100).  Al l reagents needed for 
the procedure, incl ud i ng purified Uricase, are available commercial­
ly6. 
The underlying p rinciple involved in the test is uricase enzyme 
specificity. Ur i c  ac i d  i s  the onl y  pu rine oxidized by th i s  enzyme 
6sigma Chemical Co. St . Louis , Mo. 
i n  a highly purified form (101). 
Pr i ncipl e: 
UR ICASE ) 
Uric acid 1 s  measured by a decrease in optical den s i ty in a narrow 
band; wavelength close to 292 mµ (UV ) .  
A. Methodol oey 
1.  Pipette into a test tube: 
0. 2 ml Plasma 
1.0 ml G l ycine Buffer 
6.0 ml distil led water (Mix well by shaking) 
2. Pipette into each of two cuvettes 3 . 0  m l  of mixture from 
! \... , r• • •  ,, , ' 
n L.c.i. uc; ,1 O(a e ULf·\ l \11"\  ana 
3. Pipette into the BL ANK: 
0.05 ml Ur i case 
the oi:her TEST 
Allow both to stand at room temperature fo r 1 5  minutes. 
4. a) Adjust spectrophotometer to wavelength of 292 m�. 
b) Adjust s l it width so that OD292 of BL ANK reads 0.400. 
c) Read and record OD of TEST vs  BL ANK. 
5. After approximatel y 5 minutes : 
a) Again adjust slit width so that BLANK reads 0.400. 
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b) Read and record OD of TEST . If OD has not changeQ, , 
this is considered as a "Final OD t t . If it has decreased, 
repeat readings at intervals until OD is constant. 
("Final OD") . Time required is not critical . 
B .  Calculat i ons 
1 .  Since Uricase 1 s  not used in the BLANK, the smal l  OD it 
contributes is approximately corrected for by adding 
0 . 005 to the change in OD . (Sigma Uricase has been found 
to yield approximately this OD . )  
2. A OD = ( 0 . 400 - F i nal OD) + 0. 005 
= (0 . 405 Final OD) 
3. Mg Uric Acid per 100 ml Plasma 
- (3. 05) X ( 1 68 . 1) X ( 1 00) X (AQD) 
( 1 2, 300 ) X (0 . 0833) 
-=. (50 ) X (AOD) 
C .  Explanat i on of  Factors Used i n  Calcu l at i ons 
2. 168 . 1 is the Molecular Weight of uric acid 
3. 12 , 300  is the OD of 1 mole of uric acid in 1 l i ter 
4. 100 converts 1 ml plasma to 100 m l . 
5 .  0. 0833 is the volume of plasma used 
6 .  0. 005 is the OD contributed by Uricase. 
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The OD of plasma at 292 mµ is very h igh .  Extreme care was em­
ployed in pipetting to avoid i ntroduction of significant error which 
could result if even small plasma volume changes should occur. Ace­
tone will absorb l ight in the _ same wavelength as uric ac i d  or allan­
toin . Therefore, cuvettes used i n  the procedure were air-dried 
without using acetone. 
Determ i nat i on of Plasma Trielyceride Level s 
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A commercially ava i l able Reagent Set7 was employed in measure­
ment of plasma tr i glycer i des. 
A .  Reaeents 
1. ( R-1 ) Alcohol - Ether Reagent 3 : 1 
2. (R-2 ) Hydroxylamine Hydrochloride Reagent ( 23 m l  H20 plus 
3.5 gm reagent crysta ls) . 
3. (R-3) Ferric Chlor i de Reagent, 10% in N/1 0 HCL. 
4 .  (R-4) Sodium Hydrox i de Reagent, 14% 
5 .  (R-5) Hydroch l or i c  Acid Reagent 
6 .  (R-6) Stock Standard Solution (Tributyr i n) 
7. (R-? ) Working Standard . D i lute the Stock Standard Solution 
1 to 20 with Alcohol - Ether Reagent. One ml equa ls  
0.54 mg Triglyceride .  
B .  Methodolo�y 
7 
1 .  Place 8 ml of Alcohol - Ether Reagent (R-1) in a 10 ml vol ­
umetric f lask. Add 0.3 ml pl asma. 
2 .  Heat to bo i ling in a bo il i ng water bath w i th shak i ng. 
3 .  
4 .  
Allow to cool and make up to 10 ml w i th Alcohol - Ether 
Reagent (R-1) . 
8 Fi l ter through fat-free filter paper . 
Label three cuvettes as follows : 
U - Unknown 
S - Standard 
Laboratory Diagnostics Co. Roselle ,  New Jersey . 
Whatman Filter Paper #43. W .&R. Bal ston , Limited. London. 
B - Blan k 
5. Place 3. 0 ml of filtrate 1 n  Unknown cuvette. Place 1 .0 ml (R-7) 
and 2.0 ml (R-1 )  in Standard Cuvette. Place 3. 0 ml (R-1 ) in 
Blan k cuvette . 
6. Add 0. 5 m l  of Hydroxylamine Hydrochloride Reagent (R-2) to each 
cuveHe and mix. 
7. Add 0. 5 ml of (R-4) to each cuvette and shake. 
8. Stopper all tubes and allow to stand at room temperature for 
20 minutes. 
9. Add 0. 6 ml (R-5) to each cuvette fol lowed by 0 . 5  ml (R-3) . 
Mix gently until any precipitate formed is d i ssolved. 
10. Read Un known and Standard in the colorimeter aeainst the Blank 
c .  
1 .  
at 540 m}J wavelength. 
Calculations 
Mg T riglycerides 
- OD Unknown 
OD Standard 
=- OD Unknown 









RESULTS AND D I SCUSS ION 
Data were obtained from experimental and control groups each 
conta i ning six does . Raw data obtained from body weight measurement, 
hemoglob i n  and hematocrit determ i nations and analy sis of selected 
blood lipids and ur i c  acid val ues are li sted in appendix Tables I 
through V. 
I ndiv i dual body we i ght s were recorded for all anima l s on days 
1, ? ,  14, 21 and 28 . Blood was obtained for analysis of lip i d, uric 
acid and hemogram val ues on days 7, 14, 21 and 28. 
Stat i stical Ana lysis 
An Olivetti Underwood Programma 101, self-contained, desk-top 
diPital comouter was orogramrned for statistica l ana l ysis of data . 
Standard dev i at i on ,  standard e rror , coefficient of variat i on and 
means were cal culated for data obtained sequential ly from each animal 
during the study. Analysis of data obtained from both expe r i men ta l 
and control animals grouped by col l ection dales (Days 1, 7, 14, 21 
and 28) was identical. Resul ts of initial statistical analyses are 
summarized i n  Table  V. 
Stud ent ' s t test was employed to compare d i fferences noted 
between chol e sterol , triglyceride, and uric acid values i n  experimen­
tal and cont rol groups , and the p robability value (P) obtained from 
a standard tab l e. Table V I  summar i zes statis t i cal analysis of d i f-
ferences noted between groups for each test. 
Body We ieht 
I nitial  random allocation of animals re sulted i n  placement of 
TABL E V 
MEAN AND STD . ERROR OF EACH PARAMETER MON I TORED FC R EXPER I MENTAL (E)  AND CONTROL (C) AN I MALS 
GROUPED BY DATA COLLE CT I ON DATES 
AN I MAL 
GROUP 
E Day 7 
Day 1 4  
Day 21 
Day 28 
C Day 7 




1 2 . 0  
1 1 . 8 
Hb1 (G�) 
S . E .  
0 . 4  
0 . 4  
1 2 . 2 0 . 4  
1 2 . 1 0 . 4  
1 0 . 8 0 . 3  
1 2 . 0  o . o  
1 2 . 9 o . o  
1 2 . 8 o . o  
1Hemogl ob i n · Val ues 
Hematocr i t  Values 
MEAN 
38 . 8  
37 . 8  
38 . 0  
38 . 1  
39 . 0  
37 . 3  
38 . 0  
38 . 5  
Ht2 (%) 
S . E .  
1 . 7 
1 .  0 
1 . 4 
1 . 7 
1 • 1 
0 . 8  
0 . 6  
0 . 7  
PARMtTER 
CHOLE�TEROL (WG%) TR I GLYCER I DE (WG%) 
MEA� S . E . MEAN S . E .  
63 . 3  7 . 9 202 . 6  1 7 . 7 
65 . 0  4 . 6  1 48 . 8 1 8 . 9 
64 . 2 4 . 7  66 . 9  1 1 . 5 
86 . 7  1 1 . 3 1 02 . 8  33 . 8  
77 . 1  1 2 . 5  1 74 . 9  33 . 1  
76 . 9  1 0 . 6  233 . 1  28 . 1  
78 . 8  1 0 . 4  206 . 6  23 . 2  
79 . 1  1 0 .  1 2 1 1 . 9 32 . 9  
UR I C  AC I D ( WG%) 
MEAN S . E .  
0 . 72 0 . 08 
0 . 69 0 . 07 
0 . 61 0 . 09 
0 . 48 0 . 09 
0 . 69 0 . 09 
0 . 7 1  0 . 08 
0 . 73 0 . 1 4  
0 . 78 o .  1 0  
� 
\Jl 
TABLE V I  
D I FFERENCES (WG%) BETWEEN I N I T I AL (DAY 7 ) , DAY 21 , IND TERM I NAL (DAY 28 ) CHOLESTEROL , 
TR I GLYCER I DE AND UR I C  AC I D  VALUES OBTA I NED FROM EXPE R I MENTAL (E) AND CONTROL (C ) AN I MALS 
SHOW I NG MEAN , STD. ERROR mD 1 �T 1 1  TEST RESULTS 
CHOLESTEROL TR I GLYC.� R I DES UR I C  AC I D  
AN I MAL 7-28 1 4-28 21 -28 7-28 1 1 -28 21 -28 7-28 1 4-28 21 -28 
NO . 
E 1 22 . 3  38 . 9  25 " 7  -95 . 0  4 2 .  1 88 . 6  -0 . 30 -0 . 20 -0 . 1 1  
2 o . o  3 . 3  o . o  -1 60 . 3  -93 . 6  -1 4 . 1 -0 . 41 -0 . 37 -0 . 1 3  
3 8 . 4  -4 . 9  1 . 7 -97 . 0  -8 3 . 4 -1 2 . -1 -0 . 26 -0 . 26 -0 . 1 0 
4 28 . 8  41 . 0  41 . 0  -4 . 3  2 5 . 2 1 49 . 5 -0 . 23 -0 . 21 -0 . 1 3  
5 76 .  7 55 . 5  65 . 3  -1 1 0 . 0  --52 . 7  -0 . 1  0 . 1 4  o .  1 8  -0 . 1 4  
6 5 . 0  -3 . 3  1 . 7 -1 32 . 2 -9 1 . 5  3 . 3  -0 . 42 -0 . 42 -0 . 20 
MEAN 23 . 5  21 . 8  22 . 6  -99 . 8  - 4 5 .  9 35 . 9  -0 . 25 -0 . 21 -0 . 1 4  
STD. ERROR 1 1 . 5 1 0 . 8  1 0 . 9 21 . 6  2 5 . 8  27 . 6  0 . 08 0 . 08 o . oo 
C 1 1 . 8 6 . 2 1 2 . 4  54 . 3  - 1  ) . 6  26 . 8  0 . 30 0 . 34 o .  21 
2 7 . 4  -3 . 8  -0 . 6  83 . 5  1 . 8 1 6 . 1 0 . 04 -0 . 03 0 . 01 
3 4 . 7  o . o  4 .  1 29 . 9  -2 2 . 1 -3 . 7  -0 . 02 -0 . 04 0 . 05 
4 9 . 5  4 . 8  -3 . 2  1 9 . 7  -7 3 . 5  -1 1 . 0 0 . 1 0  0 . 1 3  0 . 22 
5 -1 0 . 2  0 . 5  2 . 3  23 . 3  ·- 2 . 7 45 . 4  -0 . 08 -0 . 1 3  -0 . 39 
6 -1 . 5  4 . 8  -1 3 . 5  1 1 . 4 -2 ) . 5  -41 . 6  0 . 1 8  0 .  1 1  0 . 20 
MEAN 1 . 9 2 . 1 0 . 3  37 . 0  -2 1 . 3 5 . 3  0 . 09 0 . 06 0 . 05 
STD . ERROR 2 . 9  1 . 6 3 . 5  1 1 . 0  1 1  � 1 1 2 . 6  0 . 04 0 . 06 0 . 09 
"T' '  TEST NS NS NS ** NS NS ** * NS 
NS Not S i gn i f i cant : *S i gn i f i cant P < . 05 : **S i g1 1  i f  i cant P < . 01 
heavier does i n the control group. Stratif i cat i on of an i mals by 
we i ght following randomization was not conside r ed tenable and ad-· 
justment to a standard total body weight reference by co-va riance 
analysis was not poss ible. 
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The mean increase in we i ght of the light er experimental an i mals 
(1 67 gm) was, as expected, la rger than that of controls (110 gm) dur­
i ng the exper i mental period. Larger animals tend to gain weigh t  at 
a pace much slower than lighte r individuals when ma i nta i ned on an ad 
l i bitum feeding reg i men for sim i la r  per i ods of tim�. 
The standa rd error of the mean , of means calculat ed for body 
we i ghts of ind i vidual animals, was remarkably similar in both exper i ­
mental and control does ( 4. 0  gm) .  The refore, observed diffe r ences in 
weight ga i n  du ring the experimental pe riod between pr i ncipa l  and 
cont rol animals was attributed not to allopur i nol admin i stration but 
to phys i ologic differences i n  growth rates expected to occur between 
animals differing in initial body weight . 
Hemoelobin anq Hematocrit Values 
All hemoglob in  and hematocr i t values obtained from both expe r i -
mental and control animals we re within establ i shed normal ranges (Hb 
8. 0 - 15. 0 gm% : Ht 25. 0 - 45. 0 %) . Statist i cally s i gn i f i cant differ­
ences were not obse rved, employing the t test at the 5 pe r cent level, 
when eithe r i nd i vidual exper i mental or cont rol animals or those group-
ed by collection dates were compared . 
Expressed as mean values (of coll ect i on date group means) and one 
standard e rror of the mean, hemoglobin levels decr eased f rom a control 
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an i mal value of 12. 5 g� to 12.0 gm% i n  allopurinol t reated animals 
with a standa rd error of 0 .0 gm% in both cases. The 0 . 5  grr{% reduc­
tion i n  hemoglob i n  levels falls far short of statistical significance. 
However, recent data (91) indicating allopurinol administration may 
have an adverse effect on hepatic and total body iron storage mechan­
isms may lend additional importance to this finding .  Hemoglobin 
typing , employing electrophoret i c  techniques, should be included in 
subsequent studies on allopurinol to rule out possible p roduction 
of abnormal hemoglob i ns in animals under treatment. 
Hematocrit values exhibited very little variab i l ity in either 
control or  experimental group animals . Values expressed as means of 
either individual ani�al tests or f rom animals grouped by collection 
dates were almost identical in both animal g roups (Appendix Raw Data 
Table I I I ). 
Tota l Cho lestero l  and Trielvceride Values 
Total cholesterol levels were variable, and no statistically 
significant differences were observed, employing the t test, between 
control periods and comparable periods following drug administration 
when data was obtained from animals grouped by collection dates. 
However, comparison of mean differences between collection dates 
showed substant i al total cholesterol increases in allopurinol treated 
an i mals compared to controls (Fig. I I I) . Therefore ,  results obtained 
tend to substantiate the apparent experimentally p rovoked hypercholes­
terolemic hyperlipemia i n  rabbits administered allopurinol previously 
reported (1 ) .  Causal mechanisms are unknown and an assessment of 
cl i .n i .cal i mp l ications of the hype rcholeste rol em i c  response, i f · 
v.er i f i ed, w i ll not be poss i b l e without further stud i es .  
Although one signif i cant s-tatistical diffe rence was noted 
between in i tial and te rm i nal expe r i mental and control an i mal 
triglyceride l eve ls marked intrag roup var i ab i lity made meaningf u l  
hi�fogic inte rpretat i on i mpossible. 
Uric Ac i d  Va l ue s  
Statistically s i gnificant reduct i on s  i n u ric ac i d leve ls  were 
expected, and observed, in allopur i no l treated animals when compa red 
w.i.th controls. 
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Highly sign i f i cant (P <. 01) reduct i ons i n ur i c ac i d l evels we re 
�h�Pr\/Pn whPn d i ffP.rP.nces between i n i tial and term i nal  values were 
anaiyzed. Sign i ficant (P < . 05) reduct i ons we re obse rved i n  expe r i ­
mental animals when compar i ng diffe r ences obse rved between g roups 
monito r ed on day 1 4  and 28. D i ffe r ences between groups d u ring the 
2J to 28 day interval approached but fa i led to reach s i gn i f i can ce 
at . the five per cent level (Tabl e V I )  employ i ng the t test. 
P l asma ur i c acid alterat i ons (reductions) noted i n expe r i men tal 
an-imals we re consistent with ava i l able data wh i ch show that urate 
rave l-s fall qu i te slowly after in i tiat i on of the rapy ,  p l ateau, then 
increase to normour i cem i c  levels only gradual l y after drug withd rawl 
becaus e  of prolonged oxypurino l half-lif e  ( 75) . Pharmacolog i c ha l f­
life of effective enzyme inhibit i on is, therefore, dose-depend ent on 
allopu r i nol admin istered - and rate of oxidation to, and subsequent 
e scape or excretion of, oxypurinol (79 ) .  
R&turn- af urate levels  in experimental animals to values not 
statist.icaLLy, different f rom those of contro l does would be expec­
ted 14  day� past-treatment. 
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SUMMARY AND CONCLUS I ONS 
Effects of orally admin i stered allopurinol (hydroxyprazolo(3, 4-d) 
pyr i mid i ne) on ur i c  acid, selected blood l i p i d  and hemogram parameters 
in purebred, Dutch Black and Grey, virg i n  doe rabbits were investiga­
ted. An i mals we i gh ing 1435 to 21 14 grams were randomly  allocated to 
either an experimental or control group each contain i ng six does. 
All an i mals were maintained on a commercially available, pell i tized 
rabb i t  diet and m i neral supplement w i th feed and water provided ad 
l ib i tum. 
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Experimental an imals received 50 mg of commerc i ally available 
allopur i nol suspended in one ml of distilled water, orall y, da i ly 
for 14 days. Control group does rece i ved an equal amount of sal i ne 
for a similar period employ i ng identical techn i ques (Sham Treatment). 
Data were obtained and analyzed from both experimental and control 
animals grouped by collect ion dales. I ndiv idual body weights were 
recorded for all an imals on days 1, 7, 1 4, 21 and 28. Blood was 
drawn for analys i s of lip i d, uric ac i d  and hemogram values on days 
7, 14, 21 and 28 .  Lipid values included packed cell volume and total 
hemoglob i n. Sham treatment of controls and allopur i nol adm i nistrat i on 
in exper i mental animals began on day 7 and term i nated day 21. 
Statistical analys i s  included computat i on of standard deviat i on, 
standard error, coeffic i ent of var i at i on and means for data obta i ned 
sequential l y  from each doe and from experimental and control an i mals 
grouped by collect ion dates. The t test was employed to compare 
differences noted between cholesterol , t r i glyceride ,  and uric acid 
values in experimental and control groups, and the  p robab ility value 
(P) obtained f rom a standar d  table. 
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A greate r  mean increase i n  body weight, during the study period, 
was expected and observed in i nitially lighte r exper i mental animals 
when compared lo cont rols (wt. gain : 167 vs . 1 1 0  gm) . Observed 
diffe rences were att ributed not to allopurinol admin i st ration but to 
dispropor tionate growth rates expected to occur between an i mals 
diffe ring in initial body weight when they were maintained on a.n ad 
libitum feeding regimen for similar time periods. 
Statistically significant differences between hemoglob i n  and 
hernatocrit values were not observed . at t he 5 oer cent level . when 
either  individual expe rimental or  cont rol does or those animals 
grouped by collection dates we re compared. Howeve r, hemoglob i n level 
expressed as a mean value of collection date g roup means d ecreased 
f rom cont rol values in all opurinol t reated animals (Appendix Raw Data 
Table I I ) . All hemoglobin and hematocrit values obtained were within 
established normal ranges .  
No statistically significant differences in total cholesterol 
levels were observed between cont rol period s and comparable pe r i o d s  
following allopu rinol administ ration when data were  obtained from 
does grouped by collection d ates. However, comparison of mean 
differences between collection d ates showed substantial total 
cholesterol increases in experimental an i mals ( 22. 6 mg%) compa r ed to 
cont rols (1 . 4  mg%) and tend s to substantiate the appa rent 
hypercho l esterolem i c hyper l i pemia i n rabb i ts adm i n i stered 
_ a llopurinol prev i ously repo rted (1). 
Mar ked intragroup va r i ability made i nterpretat i on of trigl yc-
er i de values untenable. The standard er ror of seq uential tr i g l yc­
eride values (32 mg%) was substantially h i gher than that of con t rol 
animal s ( 14 mg5&) • 
Availab l e ev i dence suggests a causal relatio n sh i p  between 
53 
al l opurinol  adm i nistrat ion and f l uctuat i on s i n  blo od l ipid compo n en t s. 
However , mechan i sms are un known and an assessment of c l i nical 
imp l i cation s, if any, must await further stud i e s . 
Al lopur i nol was found highly effective i n  its  ability to lower 
bl ood ur i c acid level s. A highly significant reduct i on ( P <. 01) in 
urate revels was observed between i nit i a l (Day 7 )  and term i nal  (Day 
28) expe rimen tal an i mal uric acid val ues whe n  compared to controls. 
Sign i f i cant (P <( . 05) reduction s we re observed when compa r i ng 
differences noted between groups monitored on day 1 4 and 28. 
D i f ferences between groups during the 21 through 28 day interval 
approached but failed to reach sign i ficance at the f i ve pe r  cent 
lever •. 
1 .  
2 . 
3 .  
4 .  
5 .  
6 .  
7 • 
8 .  
9 .  
10 . 
1 1 . 
12 . 
13 . 
1 4 .  
15 . 
16 .  
1 7 .  
18. 
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APPEND I X  
RA\� DAT� TAB�E I 
BODY WEIG�T ��RAMS� Af �XP�R I MENT�L (E )  A�D CONTROL (C) �N l �Ai-� SHO�ING MEAN �ND STD� �RRO� 
i\N I MAL NO . DAY 1 DAY 7 DAY 1 4  DAY 21 DAY 28 
-
E 1 1 757 1 932 2030 2086 2044 
2 1 701  1 70 1  1 960 1 974 1 97 4  
3 ·  1 9 1 8  1 904 1 876 1 876 1 876  
4 1 435 1 505 1 547 1 533 1 477 
5 1 659 1 729 1 320 1 890 1 946  
6 1 49 1  1 589 1 631 1 645 1 645 
MEAN 1 660 1 726 1 81 0  1 834 1 827 
STD. ERROR 72 68 76 84 89 
C 1 1 673 1 687 1 70 1  1 7 1 5 1 729 
2 1 890 1 988 2) 1 6 2044 2002 
3 1 988 2044 2 )72 2030 2058 
4 2044 21 00 2 345 2401 221 2 
5 2030 1 988 2J30 20 1 6  2030 
6 1 890 21 28 2 1 84 21 28 21 42 
MEAN 1 9 1 9  1 989 2)58 2055 2028 
· STD. ERROR 55 64 86 89 67 

















RAW DATA TABLE I I 
HENDGLOBIN VALUES (GRAMS %) OF 
EXPER I MENTAL (E ) AND CONTROL (C) AN I WALS SHOW I NG MEAN AND STD. ERROR 
DAY 7 DAY 1 4  DAY 21 DAY 28 
-
1 4 . 4  1 4 . 0  1 3 . 8  1 4 . 1  
1 0 . 4  1 1 . 8 1 1 . 8 1 2 . 0  
1 0 . 8  1 0 . 2  1 0 . 2  1 0 . 2  
1 1 . 8 1 0 . 7  1 1 . 8 1 1 . 9 
1 2 . 4  1 2 . 2  1 3 . 6  1 2 . 2  
1 2 . 2  1 2 . 4  1 2 . 5  1 2 . 3  
1 2 . 0  1 1 . 8 1 2 . 2  1 2 . 1  
0 . 4  0 . 4  0 . 4  0 . 4  
1 0 . 8  1 2 . 2  1 2 . 0  1 2 . 4  
1 2 . 6  1 1 . 8 1 3 . 6  1 2 . 7 
1 3 . 8  1 1 . 8 1 3 . 8  1 2 . 3  
1 2 . 6  1 2 . 5  1 3 . 8  1 4 . 0  
1 2 . 2  1 2 . 2  1 2 . 4  1 3 . 4  
1 2 . 2  1 1 . 8 1 2 . 2  1 2 . 2  
1 2 . 3  1 2 . 0  1 2 . 9 1 2 . 8  
0 . 3  o . o o . o  o . o  
°' 
I"-) 

















RAW DATA TAB'_ E f 1 1  
HEMATOCR I T  VALUcS  (%) OF 
EXPER I MENTAL (E) AND CONTROL (C) AN I M ALS SHOW I NG MEAN AND STD . ERROR 
DAY 7 DAY 1 4  DAY 2 1  DAY 28 
-
44 41 42 43 
38 36 36 37 
33 37 32 31  
35 34 37 36 
41 40 4 1  42 
42 39 40 40 
38 . 8  37 . 8  38 . 0  38 . 1  
1 . 7 1 . 0 1 . 4 1 . 7 
35 36 37 38 
41 39 39 40 
42 36 39 38 
40 40 40 41  
40 39 38 39 
36 34 35 35 
39 . 0  37 . 3  38 . 0  38 . 5  
1 .  1 0 .. 8 0 . 6  0 . 7  
O'\ 
w 
AN I MAL NO . 
E 1 
2 













· sm . ERROR 
RA� DATA TAS:._E I Y  
TOTAL CHOLESTEROL VALUE S ( !'1G%) 
OF EXPER I MENTAL (E ) AND CONTROL (C) AN I VALS  SHOW I NG MEAN AND STD . ERROR 
DAY 7 DAY 1 4  DAY 2 1  DAY 28 
-
68 . 5  5 1 . 9  65 . 1  90 . 8  
63 . 5  60 . 2  63 . 5  63 . 5  
58 . 5  7 1 . 8  65 . 2  66 . 9  
96 . 5  83 . 9  83 . 9  1 24 . 9  
37 . 3  58 . 5  48 . 7  1 1 4 . 0  
55 . 2  63 . 5  58 . 5  60 . 2  
63 . 3  65 . 0  64 . 2  86 . 7  
7 . 9  4 . 6  4 . 7  1 1 . 3 
65 . 1  60 . 7  54 . 5  66 . 9  
66 . 9  78 . 1  74. 9 74 . 3  
59. 1 63 . 8  59 . 7  63 . 8  
62 . 2  66 . 9  74 . 9  7 1 . 7  
1 39 . 3  1 28 . 6  1 26 . 8  1 29 . 1 
70 . 1  63 . 8  82. 1 68 . 6  
77 . 1  76 . 9  78 . 8  79 .  1 
1 2 . 5  1 0 . 6  1 0 . 4  1 0 . 1  
O'\ 
.t:::,,. 
















STD . ERROR 
AAW PATA T�B�� Y 
PLASM� TRIGLYCER I DE VALUE$ (WG%) 
PF �XPE� ! ME�T� �E ),  AND CONTROL (C) ' ANIMA_S SHOWING MEAN AND STD
! 
ERROR 
DAY 7 DAY 1 4  DAY 2 1  DAY 28 
-
249 . 2 1 1 2 . 1 65 . 6  1 54 . 2  
207 . 5  1 46 . 8  6 1 . 3  47 . 2  
1 87 . 8  1 80 . 2  1 02 . 9 90 . 8  
249 . 2  21 9 . 7  95 . 4  244 . 9  
1 38 . 1 90 . 8  28 . 2  28 . 1  
1 84 . 0  1 43 . 3  48 . 5  5 1 . 8  
202 . 6  1 48 . 8  66 . 9  1 02 . 8  
1 7 . 4  1 8 . 9  1 1 . 5 33 . 8  
1 80 . 0  244 . 9  207 . 5  234 . 3  
1 36 . 2  21 7 . 6  203 . 6  21 9 . 7  
1 20 . 6  1 72 . 6 1 54 . 2 1 50 . 5  
1 32 . 6  225 . 8  1 63 . 3  1 52 . 3  
335 . 4  361 . 4  3 1 3 . 3  358 . 7  
1 44 . 6  1 76 . 5  1 97 . 6  1 56 . 0  
1 74 . 9  233 . 1  206 . 6  2 1 1 . 9 
33 . 1  28 . 1  23 . 2  32 . 9  
O'\ 
IJ1 
















STD . ERROR 
RAW DAT� TABLE ¥ f  
UR I C  ACID VALUE ! ;  (riJG%) 
OF EXPERIMENTAL (E) AND CONTROL (C) AN i f nALS SHOWING MEAN AND STD. ERROR 
DAY 7 DAY 1 4  DAY 2 1  DAY 28 
-
1 .  1 0  1 . 00 0 . 91 0 . 80 
0 . 80 0 . 76 0 . 52 0 . 39 
0 . 47 0 . 47 0 . 31 o .  21 
0 . 72 0 . 70 0 . 62 0 . 49 
0 . 55 0 . 5 1 0 . 83 0 . 69 
0 . 69 0 . 69 0 . 47 0 . 27 
0 . 72 0 . 69 0 . 61 0 . 48 
0 . 08 0 . 07 0 . 09 0 . 09 
0 . 90 0 . 86 0 . 99 1 . 20 
0 . 65 0 . 72 0 . 68 0 . 69 
0 . 49 0 . 51 0 . 42 0 . 47 
0 . 7 1  0 . 68 0 . 59 0 . 81 
0 . 99 1 . 04 1 . 30 0 . 9 1 
0 . 39 0 . 46 0 . 37 0 . 57 
0 . 69 o .  7 1  0 . 73 0 . 78 
0 . 09 0 . 08 0 . 1 4  . 0 . 1 0  
°' 
O'\ 
